Benzinga | Nov 5, 2021 09:45AM EDT

Chardan Capital Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $17

Chardan Capital analyst Keay Nakae initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $17.